Tilray Brands, Inc. (TLRY) stock
TLRYNasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends May 31
Financials through Q1 FY2027, quarter ended Aug 31, 2026Last filing: 10-Q on Oct 8, 2026Score 11/3087% below fair value
$2.25−0.10 (-4.26%)
Close on Nov 18, 2026Market cap $332.52MP/E –Yield –
Tilray Brands revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Tilray Brands's revenue for the twelve months ending Aug 31, 2026 was $963.10M, up 15.9% year over year. For fiscal 2026 it was $915.45M, up 11.5% from the year before. The highest annual figure on record is $915.45M in fiscal 2026.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | May 31, 2026 | $915.45M | +11.5% |
| FY2025 | May 31, 2025 | $821.31M | +4.1% |
| FY2024 | May 31, 2024 | $788.94M | +25.8% |
| FY2023 | May 31, 2023 | $627.12M | -0.2% |
| FY2022 | May 31, 2022 | $628.37M | +276.3% |
| FY2019 | Dec 31, 2019 | $166.98M | +287.2% |
| FY2018 | Dec 31, 2018 | $43.13M | +110.0% |
| FY2017 | Dec 31, 2017 | $20.54M | +62.4% |
| FY2016 | Dec 31, 2016 | $12.64M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2027CQ3 2026 | Aug 31, 2026 | $257.15M | +22.7% |
| Q4 FY2026CQ2 2026 | May 31, 2026 | $281.71M | +25.5% |
| Q3 FY2026CQ1 2026 | Feb 28, 2026 | $206.73M | +11.3% |
| Q2 FY2026CQ4 2025 | Nov 30, 2025 | $217.51M | +3.1% |
| Q1 FY2026CQ3 2025 | Aug 31, 2025 | $209.50M | +4.7% |
| Q4 FY2025CQ2 2025 | May 31, 2025 | $224.54M | -2.3% |
| Q3 FY2025CQ1 2025 | Feb 28, 2025 | $185.78M | -1.4% |
| Q2 FY2025CQ4 2024 | Nov 30, 2024 | $210.95M | +8.9% |
| Q1 FY2025CQ3 2024 | Aug 31, 2024 | $200.04M | +13.1% |
| Q4 FY2024CQ2 2024 | May 31, 2024 | $229.88M | +24.8% |
| Q3 FY2024CQ1 2024 | Feb 29, 2024 | $188.34M | +29.4% |
| Q2 FY2024CQ4 2023 | Nov 30, 2023 | $193.77M | +34.4% |
| Q1 FY2024CQ3 2023 | Aug 31, 2023 | $176.95M | +15.5% |
| Q4 FY2023CQ2 2023 | May 31, 2023 | $184.19M | +20.1% |
| Q3 FY2023CQ1 2023 | Feb 28, 2023 | $145.59M | -4.1% |
| Q2 FY2023CQ4 2022 | Nov 30, 2022 | $144.14M | -7.1% |
| Q1 FY2023CQ3 2022 | Aug 31, 2022 | $153.21M | -8.8% |
| Q4 FY2022CQ2 2022 | May 31, 2022 | $153.33M | +226.7% |
| Q3 FY2022CQ1 2022 | Feb 28, 2022 | $151.87M | +197.2% |
| Q2 FY2022CQ4 2021 | Nov 30, 2021 | $155.15M | +238.0% |
| Q1 FY2022CQ3 2021 | Aug 31, 2021 | $168.02M | +629.3% |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | $46.94M | +202.2% |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | $51.10M | +408.6% |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | $45.90M | +371.1% |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | $23.04M | +195.1% |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | $15.53M | +203.8% |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | $10.05M | +85.8% |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | $9.74M | +95.2% |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | $7.81M | +55.3% |
| Q4 FY2017CQ4 2017 | Dec 31, 2017 | $5.11M | – |
| Q3 FY2017CQ3 2017 | Sep 30, 2017 | $5.41M | – |
| Q2 FY2017CQ2 2017 | Jun 30, 2017 | $4.99M | – |
| Q1 FY2017CQ1 2017 | Mar 31, 2017 | $5.03M | – |
See a number that looks wrong?